Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Latest Information Update: 25 Sep 2023
Price :
$35 *
At a glance
- Drugs Docetaxel (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 20 Jul 2023 Status changed from active, no longer recruiting to completed.
- 30 Mar 2020 Planned End Date changed from 1 Dec 2020 to 30 Dec 2020.
- 23 Dec 2019 Planned End Date changed from 1 Oct 2019 to 1 Dec 2020.